Expansion brings firm’s total US manufacturing commitment over the last year to nearly $2 billion.
Amgen is directing an additional $300 million in its US manufacturing operations in Juncos, Puerto Rico, to boost production capacity and enhance next-generation technologies.
Robert Bradway, Chairman and Chief Executive Officer, Amgen, said the investment will help “patients have access to the medicines they need, investing in the long-term strength of our domestic supply chain and supporting American jobs”, particularly for its existing advanced manufacturing roles in the region.
The news builds on the firm’s multiple planned US investments announced over the past year, totalling nearly $2 billion. This includes $900 million in Ohio last April, in September 2025 investing $650 million in its Puerto Rico manufacturing operations and $600 million in a science and innovation centre in California.
Since 2024, Amgen has channelled over $1.5 billion in North Carolina. Since 2017, the company has committed over $40 billion in manufacturing and R&D development in the US.
Combined with the $650 million previously announced, [Amgen’s additional $300 million commitment in Juncos] represents nearly $1 billion in confidence in our workforce, our capabilities and our ability to produce life‑saving medicines”
Sebastián Negrón Reichard, Puerto Rico Secretary of the Department of Economic Development and Commerce, added: “Amgen’s additional $300 million commitment in Juncos is a powerful signal that the future of American biomanufacturing is being built here. Combined with the $650 million previously announced, this represents nearly $1 billion in confidence in our workforce, our capabilities and our ability to produce life‑saving medicines.”
Alongside Amgen, Novartis is another major pharmaceutical company that has recently increased its US investment quota. Part of Novartis’ $23 billion commitment in its US operations, the firm announced plans for a new facility in Morrisville, North Carolina, strengthening its end‑to‑end production capability.
Furthermore, biopharmaceutical company UCB plans to build a new biologics manufacturing facility in Georgia, US. Just as Amgen’s latest US investment aims to advance next-generation technologies, UCB’s new plant in Gwinnett County is set to incorporate a digital-first approach, leveraging AI, robotics and automation to enable continuous medicine production.
No comments yet